This phase 2 trial tests whether adding an experimental drug called onvansertib to standard chemotherapy and bevacizumab can shrink tumors better than chemo alone in people with advanced colorectal cancer that has a KRAS or NRAS mutation. About 110 participants who have not had p…
Phase: PHASE2 • Sponsor: Cardiff Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC